Phase I study of iproplatin in pediatric patients: A Pediatric Oncology study group

C. B. Pratt; B. A. Kamen; N. Winick; P. Sartain; J. E. Champion; A. H. Ragab; M. P. Goren

Phase I study of iproplatin in pediatric patients: A Pediatric Oncology study group

C. B. Pratt, B. A. Kamen, N. Winick, P. Sartain, J. E. Champion, A. H. Ragab, M. P. Goren

Research output: Contribution to journal › Article › peer-review

Abstract

Iproplatin was evaluated in a phase I study in children to determine the maximum tolerated dosage. The dose limiting toxic effect was found to be myelosuppression, which in part was related to the amount of prior therapy with irradiation and other anticancer agents. The dosage recommended for phase II trials in children is 324 mg/m² iv over 2 hours every 3-4 weeks.

Original language	English (US)
Pages (from-to)	87-88
Number of pages	2
Journal	Cancer treatment reports
Volume	71
Issue number	1
State	Published - 1987

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{cf1db27a23e34f558021b3ea37e823b7,

title = "Phase I study of iproplatin in pediatric patients: A Pediatric Oncology study group",

abstract = "Iproplatin was evaluated in a phase I study in children to determine the maximum tolerated dosage. The dose limiting toxic effect was found to be myelosuppression, which in part was related to the amount of prior therapy with irradiation and other anticancer agents. The dosage recommended for phase II trials in children is 324 mg/m2 iv over 2 hours every 3-4 weeks.",

author = "Pratt, {C. B.} and Kamen, {B. A.} and N. Winick and P. Sartain and Champion, {J. E.} and Ragab, {A. H.} and Goren, {M. P.}",

year = "1987",

language = "English (US)",

volume = "71",

pages = "87--88",

journal = "Cancer treatment reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Phase I study of iproplatin in pediatric patients

T2 - A Pediatric Oncology study group

AU - Pratt, C. B.

AU - Kamen, B. A.

AU - Winick, N.

AU - Sartain, P.

AU - Champion, J. E.

AU - Ragab, A. H.

AU - Goren, M. P.

PY - 1987

Y1 - 1987

N2 - Iproplatin was evaluated in a phase I study in children to determine the maximum tolerated dosage. The dose limiting toxic effect was found to be myelosuppression, which in part was related to the amount of prior therapy with irradiation and other anticancer agents. The dosage recommended for phase II trials in children is 324 mg/m2 iv over 2 hours every 3-4 weeks.

AB - Iproplatin was evaluated in a phase I study in children to determine the maximum tolerated dosage. The dose limiting toxic effect was found to be myelosuppression, which in part was related to the amount of prior therapy with irradiation and other anticancer agents. The dosage recommended for phase II trials in children is 324 mg/m2 iv over 2 hours every 3-4 weeks.

UR - http://www.scopus.com/inward/record.url?scp=0023130855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023130855&partnerID=8YFLogxK

M3 - Article

C2 - 3791272

AN - SCOPUS:0023130855

SN - 0361-5960

VL - 71

SP - 87

EP - 88

JO - Cancer treatment reports

JF - Cancer treatment reports

IS - 1

ER -

Phase I study of iproplatin in pediatric patients: A Pediatric Oncology study group

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this